AlzeCure Receives $10M Upfront Payment From Lilly
Stockholm, Sweden, August 18, 2026 AlzeCure Pharma AB has received the full $10 million upfront payment from Eli Lilly...
CNS drug development
Advertisement
Cipla Receives FDA Nod for Generic Advair Diskus
MUMBAI, India and WARREN, N.J., July 28, 2026 Cipla Limited and its wholly owned subsidiary Cipla USA Inc. have...
CORE Biomedicine Secures $21M Series A Funding
BOSTON, TOKYO and SUZHOU, July 28, 2026 CORE Biomedicine, a biotechnology company advancing lineage-based precision oncology therapeutics, has announced...
Co-Diagnostics Advances Ebola Testing Innovation Globally
SALT LAKE CITY, July 28, 2026 Co-Diagnostics, Inc. has announced two significant milestones that strengthen global preparedness against Ebola...
Dasher Neuroscience Advances YA-101 Phase 2 Trial
TAIPEI, July 28, 2026 Dasher Neuroscience Holdings Inc. has successfully completed patient enrollment in its global Phase 2 clinical...
Advertisements
Rapport, Tenacia Partner to Develop RAP-219 in China
Boston, USA & Shanghai, China – March 9, 2026 Rapport Therapeutics and Tenacia Biotechnology have announced a strategic collaboration...
Omalizumab Matches Multi-Food Immunotherapy in Allergy Trial
MILWAUKEE, Feb. 22, 2026 — New clinical research presented at the 2026 Annual Meeting of the American Academy of...
FDA Approves BYSANTI for Bipolar I and Schizophrenia
WASHINGTON, Feb. 20, 2026 — Vanda Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™...
Meta-Analysis Reveals Drivers of Placebo Response in GAD
BOSTON, Feb. 20, 2026 — Seaport Therapeutics announced new findings from a comprehensive meta-analysis examining how clinical trial design...
Alto Completes Phase 2 Enrollment for CIAS Drug
MOUNTAIN VIEW, Calif., Feb. 13, 2026 — Alto Neuroscience announced completion of patient enrollment in its Phase 2 proof-of-concept...
Advertisement
